Search

Your search keyword '"Mastroianni‐Kirsztajn, Gianna"' showing total 173 results
Start Over Author "Mastroianni‐Kirsztajn, Gianna"
173 results on '"Mastroianni‐Kirsztajn, Gianna"'

2. Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study

Author

Hullekes, Frank, Uffing, Audrey, Verhoeff, Rucháma, Seeger, Harald, von Moos, Seraina, Mansur, Juliana, Mastroianni-Kirsztajn, Gianna, Silva, Helio Tedesco, Buxeda, Anna, Pérez-Sáez, María José, Arias-Cabrales, Carlos, Collins, A. Bernard, Swett, Christie, Morená, Leela, Loucaidou, Marina, Kousios, Andreas, Malvezzi, Paolo, Bugnazet, Mathilde, Russo, Luis Sanchez, Muhsin, Saif A., Agrawal, Nikhil, Nissaisorakarn, Pitchaphon, Patel, Het, Al Jurdi, Ayman, Akalin, Enver, Neto, Elias David, Agena, Fabiana, Ventura, Carlucci, Manfro, Roberto C., Bauer, Andrea Carla, Mazzali, Marilda, de Sousa, Marcos Vinicius, La Manna, Gaetano, Bini, Claudia, Comai, Giorgia, Reindl-Schwaighofer, Roman, Berger, Stefan, Cravedi, Paolo, and Riella, Leonardo V.

Published
2024
Full Text
View/download PDF

5. Nephrology in Brazil

Author

Moura-Neto, José A., Silva, Cassiano Augusto Braga, Ponce, Daniela, Mastroianni Kirsztajn, Gianna, Medina Pestana, José Osmar, Foresto, Renato Demarchi, Moura, Ana Flavia, Martins, Carmen Tzanno Branco, Souza, Edison, do Nascimento, Marcelo Mazza, Suassuna, José Hermógenes Rocco, Moura-Neto, José A., editor, Divino-Filho, José Carolino, editor, and Ronco, Claudio, editor

Published
2021
Full Text
View/download PDF

8. Estimated glomerular filtration rate in clinical practice: Consensus positioning of the Brazilian Society of Nephrology (SBN) and Brazilian Society of Clinical Pathology and Laboratory Medicine (SBPC/ML).

Author

Mastroianni Kirsztajn, Gianna, Bezerra da Silva Junior, Geraldo, Bezerra da Silva, Artur Quintiliano, Abensur, Hugo, Egídio Romão Junior, João, Gomes Bastos, Marcus, Calice-Silva, Viviane, de Freitasdo Carmo, Lilian Pires, Veras de Sandes-Freitas, Tainá, Ferreira Abreu, Patrícia, Dolci Andreguetto, Bruna, Ferreira Cortes, Luiz Gustavo, de Lucca Oliveira, Maria Gabriela, Falci Vieira, Luisane Maria, Moura-Neto, José A., and Andriolo, Adagmar

Published
2024
Full Text
View/download PDF

9. COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases

Author

Gauckler, Philipp, primary, Kesenheimer, Jana S., additional, Geetha, Duvuru, additional, Odler, Balazs, additional, Eller, Kathrin, additional, Laboux, Timothee, additional, Alberici, Federico, additional, Zappa, Mattia, additional, Chebotareva, Natasha, additional, Moiseev, Sergey, additional, Bonilla, Marco, additional, Jhaveri, Kenar D., additional, Oniszczuk, Julie, additional, Audard, Vincent, additional, Costa, Denise, additional, Mastroianni-Kirsztajn, Gianna, additional, Bruchfeld, Annette, additional, Muto, Masahiro, additional, Windpessl, Martin, additional, Mayer, Gert, additional, and Kronbichler, Andreas, additional

Published
2023
Full Text
View/download PDF

12. COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases

Author

Gauckler, Philipp, Kesenheimer, Jana S., Geetha, Duvuru, Odler, Balazs, Eller, Kathrin, Laboux, Timothee, Alberici, Federico, Zappa, Mattia, Chebotareva, Natasha, Moiseev, Sergey, Bonilla, Marco, Jhaveri, Kenar D., Oniszczuk, Julie, Audard, Vincent, Costa, Denise, Mastroianni-Kirsztajn, Gianna, Bruchfeld, Annette, Muto, Masahiro, Windpessl, Martin, Mayer, Gert, Kronbichler, Andreas, Gauckler, Philipp, Kesenheimer, Jana S., Geetha, Duvuru, Odler, Balazs, Eller, Kathrin, Laboux, Timothee, Alberici, Federico, Zappa, Mattia, Chebotareva, Natasha, Moiseev, Sergey, Bonilla, Marco, Jhaveri, Kenar D., Oniszczuk, Julie, Audard, Vincent, Costa, Denise, Mastroianni-Kirsztajn, Gianna, Bruchfeld, Annette, Muto, Masahiro, Windpessl, Martin, Mayer, Gert, and Kronbichler, Andreas

Abstract

Introduction: Patients with immune-mediated glomerular diseases are considered at high risk for severe COVID-19 outcomes. However, conclusive evidence for this patient population is scarce.Methods: We created a global registry and retrospectively collected clinical data of patients with COVID-19 and a previously diagnosed immune-mediated glomerular disease to characterize specific risk factors for severe COVID-19 outcomes.Results: Fifty-nine patients with a history of immune-mediated glomerular diseases were diagnosed with COVID-19 between 01.03.2020 and 31.08.2021. Over a mean follow-up period of 24.79 +/- 18.89 days, ten patients (16.9%) developed acute kidney injury. Overall, 44.1% of patients were managed in an outpatient setting and therefore considered as having "non-severe" COVID-19, while 55.9% of patients had severe COVID-19 requiring hospitalization including worse outcomes. Comparing both groups, patients with severe COVID-19 were significantly older (53.55 +/- 17.91 versus 39.77 +/- 14.95 years, p = .003), had lower serum albumin levels at presentation (3.00 +/- 0.80 g/dL versus 3.99 +/- 0.68 g/dL, p = .016) and had a higher risk of developing acute kidney injury (27% versus 4%, p = .018). Male sex (p <.001) and ongoing intake of corticosteroids at presentation (p = .047) were also significantly associated with severe COVID-19 outcomes, while the overall use of ongoing immunosuppressive agents and glomerular disease remission status showed no significant association with the severity of COVID-19 (p = .430 and p = .326, respectively).Conclusion: Older age, male sex, ongoing intake of corticosteroids and lower serum albumin levels at presentation were identified as risk factors for severe COVID-19 outcomes in patients with a history of various immune-mediated glomerular diseases., Funding Agencies|The authors thank Lalit Kaltenbach for his support with the creation and administration of the REDCap database.

Published
2023
Full Text
View/download PDF

18. Development of an instrument to predict proliferative histological class in lupus nephritis based on clinical and laboratory data.

Author

Silaide de Araújo Júnior, Antônio, Sato, Emília I, Silva de Souza, Alexandre W, Jennings, Fábio, Mastroianni Kirsztajn, Gianna, Sesso, Ricardo, and dos Reis-Neto, Edgard T

Subjects
PATHOLOGICAL laboratories, RENAL biopsy, SYSTEMIC lupus erythematosus, URINALYSIS, INDEPENDENT variables
Abstract

Objectives: To compare the correlations of histological class inferences based on clinical manifestations and laboratory tests between rheumatologists and nephrologists, to determine the associations of clinical and laboratory data with histological classes and to develop an instrument that can assist histological class identification in lupus nephritis (LN). Methods: Retrospective study based on medical records of 80 systemic lupus erythematosus patients (SLICC criteria classification, 2012) who underwent kidney biopsy between 2010 and 2017. Two rheumatologists and two nephrologists received clinical and laboratory data and answered questions regarding which histological class was expected on kidney biopsy. Kappa (K) coefficient was used to assess agreement between evaluators. A decision tree was constructed using the chi-square interaction detector and logistic regression was performed for the development of the proliferative histological class predictor instrument. Results: The mean age and disease duration were 33 ± 10.3 years and 11.5 ± 6.7 years, respectively. The level of agreement between the evaluators and kidney biopsy was poor (global K 0.364 ± 0.029; p <.001). Analyzing clinical and laboratory variables as predictors of proliferative histological class, patients with abnormal urinary sediment and positive anti-dsDNA antibodies presented 13.96 and 4.96 times higher risks of presenting class III or IV, respectively (p < 0.001). Our instrument has a sensitivity of 87.8% and specificity of 80%, using abnormal urinary sediment, anti-dsDNA antibodies, and serum creatinine as variables. Conclusions: Rheumatologists and nephrologists with experience in treating LN generated evaluations that correlated weakly with kidney biopsy. When kidney biopsy is unavailable or is contraindicated for medical reasons, instruments based on clinical and laboratory predictors may be helpful. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Recurrence of IgA Nephropathy after Kidney Transplantation in Adults

Author

Uffing, Audrey, primary, Pérez-Saéz, Maria José, additional, Jouve, Thomas, additional, Bugnazet, Mathilde, additional, Malvezzi, Paolo, additional, Muhsin, Saif A., additional, Lafargue, Marie-Camille, additional, Reindl-Schwaighofer, Roman, additional, Morlock, Alina, additional, Oberbauer, Rainer, additional, Buxeda, Anna, additional, Burballa, Carla, additional, Pascual, Julio, additional, von Moos, Seraina, additional, Seeger, Harald, additional, La Manna, Gaetano, additional, Comai, Giorgia, additional, Bini, Claudia, additional, Russo, Luis Sanchez, additional, Farouk, Samira, additional, Nissaisorakarn, Pitchaphon, additional, Patel, Het, additional, Agrawal, Nikhil, additional, Mastroianni-Kirsztajn, Gianna, additional, Mansur, Juliana, additional, Tedesco-Silva, Hélio, additional, Ventura, Carlucci Gualberto, additional, Agena, Fabiana, additional, David-Neto, Elias, additional, Akalin, Enver, additional, Alani, Omar, additional, Mazzali, Marilda, additional, Manfro, Roberto Ceratti, additional, Bauer, Andrea Carla, additional, Wang, Aileen X., additional, Cheng, Xingxing S., additional, Schold, Jesse D., additional, Berger, Stefan P., additional, Cravedi, Paolo, additional, and Riella, Leonardo V., additional

Published
2021
Full Text
View/download PDF

33. Paulista registry of glomerulonephritis: 5-year data report

Author

Malafronte, Patricia, Mastroianni-Kirsztajn, Gianna, Betônico, Gustavo N., Romão, João Egídio, Jr, Alves, Maria Almerinda R., Carvalho, Maria Fernanda, Viera Neto, Osvaldo M., Cadaval, Ricardo A. M., Bérgamo, Ronaldo R., Woronik, Viktória, Sens, Yvoty A. S., Marrocos, Mauro S. M., and Barros, Rui T.

Published
2006

37. Pre-exposure prophylaxis during the SARS-CoV-2 pandemic: can PrEP prevent COVID-19-related symptoms?

Author

Euclides Fernandes, Danilo, Abrão Ferreira, Paulo Roberto, and Mastroianni Kirsztajn, Gianna

Abstract

It has been speculated that some drugs can be used against SARS-CoV-2. As for antiretrovirals, the follow-up of pre-exposure prophylaxis (PrEP) users during the coronavirus disease 2019 (COVID-19) outbreak may help to understand the potential protective effect of PrEP against SARS-CoV-2. We aimed to identify associations between oral PrEP use and COVID-19-related symptoms self-reporting. Phone call interviews or digital investigation (through WhatsApp® or e-mail) about oral PrEP regular use, social distancing, exposure to suspected or confirmed cases of SARS-CoV-2 infection and COVID-19-related symptoms. Among 108 individuals, the majority were cisgender, white and gay men. Although most of the individuals engaged in social distancing (68.52%), they kept on taking PrEP (75.93%). Few people have had contact with suspected or confirmed cases of COVID-19 (12.04%), but some had COVID-19-related symptoms the month before the interview (27.78%) including rhinorrheoa (56.67%), cough (53.33%), asthaenia (50.00%) and headache (43.33%). Also, oral PrEP was associated with lower self-reporting COVID-19-symptoms (OR 0.26, 95% CI 0.07–0.96, P = 0.04; h = 0.92) even after controlling confounders as social distancing, age, body-mass index and morbidities . In our sample, the regular use of oral PrEP was associated with lower self-reporting of COVID-19-related symptoms during the outbreak in São Paulo, Brazil. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

40. Functional Characterization and Pharmacological Evaluation of a Novel GLAMissense Mutation Found in a Severely Affected Fabry Disease Family

Author

Varela, Patrícia, Mastroianni Kirsztajn, Gianna, Ferrer, Henrique, Aranda, Carolina, Wallbach, Krissia, Ferreira da Mata, Gustavo, Moura, Luiz A., Moreira, Sílvia R., Mendes, Carmen, Curiati, Marco A., Martins, Ana Maria, and Bosco Pesquero, João

Abstract

Background:Fabry disease (FD) is a rare X-linked storage disorder resulting from the deficient activity of the lysosomal hydrolase α-galactosidase A (α-Gal A). Here we describe a 23-year-old man with FD possessing a novel mutation in the GLAgene, the evaluation of his family, and the functional characterization of the novel variant. Methods:Two generations of a family were screened for FD by clinical symptoms and low enzymatic activity. This step was followed by DNA sequencing that showed a novel GLAmissense mutation. To confirm the pathogenicity potential of the mutation, we employed site-directed polymerase chain reaction mutagenesis. GLAwild-type and mutant plasmids were transfected into mammalian cells; RNA and proteins were extracted for expression and analysis of enzymatic activity. Results:The patient presents the variant p.Asn34Asp in the GLAand had several manifestations of FD since adolescence. The investigation of the deficiency of α-Gal A was initiated due to stage 4 of chronic kidney disease. All family members carrying the novel mutation presented early symptoms, including index case’s mother, who received a renal transplant when she was 35 years old. In silicoand in vitro analysis confirmed the pathogenic potential of the mutation p.Asn34Asp showing that the enzyme had only 4% of residual activity due to protein misfolding. The ability of the pharmacological chaperone 1-deoxygalactonojirimycin to recover the mutant was confirmed, producing 37.5% of residual activity. Conclusion:In this work, we present a novel missense mutation in GLAthat leads to the production of a catalytically competent α-Gal A, which is degraded before its delivery to the lysosome, promoting severe manifestations of FD, with a very similar disease course in affected men and women.

Published
2020
Full Text
View/download PDF

42. Prevalence of APOL1 Variants in Persons with Proteinuric CKD

Author

Bramham, Kate, Knebelmann, Bertrand, Audard, Vincent, Boffa, Jean-Jacques, Echeverri, Diego, Mccafferty, Kieran, Powell, Thomas, Provenzano, Christopher, Shahid, Nauman, Zaidan, Mohamad, Torres, Pablo A. Urena, Mastroianni-Kirsztajn, Gianna, Zamauskaite, Aurelia, Delestre-Levai, Irisz K., Bauman, John, Yang, Yuan, Krause, Silva, Ferreira, Anna, Egbuna, Ogo I., and Chertow, Glenn

Published
2023
Full Text
View/download PDF

48. [216-POS]

Author

Facca, Thais A., primary, Sabino, Amelia R., additional, Sato, Jussara, additional, Fama, Eduado A., additional, Junior, Guilherme S., additional, Mastroianni-Kirsztajn, Gianna, additional, and Sass, Nelson, additional

Published
2015
Full Text
View/download PDF

49. Aspectos psicológicos de pacientes com lúpus eritematoso sistêmico: uma revisão

Author

BARROS, Bruna Paes de, SOUZA, Camila Bernardes de, and MASTROIANNI-KIRSZTAJN, Gianna

Subjects
Revisão, Aspectos psicológicos, Lúpus eritematoso sitêmico
Abstract

BARROS, Bruna Paes de; SOUZA, Camila Bernardes de; MASTROIANNI-KIRSZTAJN, Gianna. Aspectos psicológicos de pacientes com lúpus eritematoso sistêmico: uma revisão. Revista de Psicologia, Fortaleza, v.22, n.1, 2004, p 09-14. This review study about psychological aspects of patients with Systemic Lupus Erythematusus (SLE)has the intention to show to the mental health professionals that there is a need of complementing the approach to the SLE patients, and that there are new applicable interventions, from prevention to rehabilitation of these patients. As this disease is multifactorial and chronic, the health professionals have to be aware of neurologic, psyquiatric, psychossomatic and psychologic aspects, but also of the full context of the patient, as social, cultural, economic, biologic and spiritual condition, according to the definition of health of World Health Organization. We show that many studies about patients with SLE conclude that the multidisciplinary treatment should be provided to these patients. Esta revisão de artigos científicos a respeito dos aspectos psicológicos de pacientes com Lúpus Eritematoso Sistêmico (LES) teve a intenção de mostrar aos profissionais de saúde mental a necessidade de complementação da abordagem e de novas possibilidades intervencionistas, da prevenção à reabilitação desses pacientes. Em se tratando de uma doença multifatorial e crônica, como profissionais da saúde, devemos atentar não somente para aspectos neurológicos, psiquiátricos, psicossomáticos e psicológicos, mas também para o contexto biopsicossocial desses pacientes: sua condição social, cultural, econômica, biológica e espiritual, de acordo com o que propõe a definição de saúde da Organização Mundial de Saúde. Mostramos que diversos estudos sobre pacientes com LES concluem que o tratamento multidisciplinar deve ser fornecido a esses pacientes, que são portadores de uma doença sistêmica e crônica.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results